1L CT (HR+HER2-): Active treatments
Vinorelbine (oral) RWD
Heudel et al SABCS 2016
N=1402 patients who had received OV during the course of their disease
•
282 patients novo metastatic disease (20.1%)
•
median time between initial diagnosis and metastatic diagnosis was 59.8 mo
•
At metastatic diagnosis, 569 patients (40.6%) had only non-visceral mtx
•
994 patients (72.8%) received OV as initial drug in the line and 370 patients (17.1%) as maintenance therapy
•
OV is administered with specific patterns according to the
treatment lines and mainly as maintenance therapy in 1L
treatment (maintenance CT may be a reasonable strategy)
